Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)

BACKGROUND: Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA). Bone and joint infections represent a complex set of diseases requiring prolonged antimicrobi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sims, Charles, Bressler, Adam, Lacy, Melinda, Osmukhina, Anna, Castaneda-Ruiz, Bibiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632217/
http://dx.doi.org/10.1093/ofid/ofx163.052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632217/
http://dx.doi.org/10.1093/ofid/ofx163.052

Ejemplares similares